Literature DB >> 24333417

IRS1Ser³⁰⁷ phosphorylation does not mediate mTORC1-induced insulin resistance.

Hilde Herrema1, Jaemin Lee1, Yingjiang Zhou1, Kyle D Copps1, Morris F White1, Umut Ozcan2.   

Abstract

Increased mammalian target of rapamycin complex 1 (mTORC1) activity has been suggested to play important roles in development of insulin resistance in obesity. mTORC1 hyperactivity also increases endoplasmic reticulum (ER) stress, which in turn contributes to development of insulin resistance and glucose intolerance. Increased IRS1 phosphorylation at Ser307 in vitro is correlated with mTORC1- and ER stress-induced insulin resistance. This phosphorylation site correlates strongly with impaired insulin receptor signaling in diabetic mice and humans. In contrast, evidence from knock-in mice suggests that phosphorylation of IRS1 at Ser307 is actually required to maintain insulin sensitivity. To study the involvement of IRS1(Ser307) phosphorylation in mTORC1-mediated glucose intolerance and insulin sensitivity in vivo, we investigated the effects of liver specific TSC1 depletion in IRS1(Ser307Ala) mice and controls. Our results demonstrate that blockade of IRS1(Ser307) phosphorylation in vivo does not prevent mTORC1-mediated glucose intolerance and insulin resistance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; ER stress; IRS1; mTORC1

Mesh:

Substances:

Year:  2013        PMID: 24333417      PMCID: PMC3926104          DOI: 10.1016/j.bbrc.2013.12.023

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  40 in total

Review 1.  Quality control in the endoplasmic reticulum.

Authors:  Lars Ellgaard; Ari Helenius
Journal:  Nat Rev Mol Cell Biol       Date:  2003-03       Impact factor: 94.444

2.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

3.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Authors:  Robbie Loewith; Estela Jacinto; Stephan Wullschleger; Anja Lorberg; José L Crespo; Débora Bonenfant; Wolfgang Oppliger; Paul Jenoe; Michael N Hall
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

4.  The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).

Authors:  V Aguirre; T Uchida; L Yenush; R Davis; M F White
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

5.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

6.  Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.

Authors:  Yong Zhang; Xinsheng Gao; Leslie J Saucedo; Binggen Ru; Bruce A Edgar; Duojia Pan
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

7.  Rheb promotes cell growth as a component of the insulin/TOR signalling network.

Authors:  Leslie J Saucedo; Xinsheng Gao; Dominic A Chiarelli; Ling Li; Duoija Pan; Bruce A Edgar
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

8.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Authors:  Attila Garami; Fried J T Zwartkruis; Takahiro Nobukuni; Manel Joaquin; Marta Roccio; Hugo Stocker; Sara C Kozma; Ernst Hafen; Johannes L Bos; George Thomas
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

9.  Lifetime risk for diabetes mellitus in the United States.

Authors:  K M Venkat Narayan; James P Boyle; Theodore J Thompson; Stephen W Sorensen; David F Williamson
Journal:  JAMA       Date:  2003-10-08       Impact factor: 56.272

Review 10.  Potential for therapeutic manipulation of the UPR in disease.

Authors:  Sang Won Park; Umut Ozcan
Journal:  Semin Immunopathol       Date:  2013-04-10       Impact factor: 9.623

View more
  6 in total

1.  G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway.

Authors:  Nathan C Law; Morris F White; Mary E Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2016-11-17       Impact factor: 5.157

2.  Aberrant REDD1-mTORC1 responses to insulin in skeletal muscle from Type 2 diabetics.

Authors:  David L Williamson; Cory M Dungan; Abeer M Mahmoud; Jacob T Mey; Brian K Blackburn; Jacob M Haus
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-12       Impact factor: 3.619

3.  Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.

Authors:  Kyle D Copps; Nancy J Hançer; Wei Qiu; Morris F White
Journal:  J Biol Chem       Date:  2016-02-04       Impact factor: 5.157

4.  Voluntary Exercise Can Ameliorate Insulin Resistance by Reducing iNOS-Mediated S-Nitrosylation of Akt in the Liver in Obese Rats.

Authors:  Takamasa Tsuzuki; Shohei Shinozaki; Hideko Nakamoto; Masao Kaneki; Sataro Goto; Kentaro Shimokado; Hiroyuki Kobayashi; Hisashi Naito
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 5.  Endoplasmic Reticulum Stress in Metabolic Disorders.

Authors:  Rose Ghemrawi; Shyue-Fang Battaglia-Hsu; Carole Arnold
Journal:  Cells       Date:  2018-06-19       Impact factor: 6.600

6.  dbPTM in 2019: exploring disease association and cross-talk of post-translational modifications.

Authors:  Kai-Yao Huang; Tzong-Yi Lee; Hui-Ju Kao; Chen-Tse Ma; Chao-Chun Lee; Tsai-Hsuan Lin; Wen-Chi Chang; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.